We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genomics and AI-Powered Urine Infectious Disease Test Addresses Critical Need for Complicated UTIs

By LabMedica International staff writers
Posted on 02 Jan 2025

Urinary tract infections (UTIs) are the most prevalent outpatient infection, affecting over 7 million patients annually, with women being disproportionately impacted. More...

UTIs can severely affect the quality of life and lead to significant health complications. Around 30% of sepsis cases stem from the urogenital tract, with immunocompromised patients being at a higher risk of developing urosepsis. Current diagnostic methods are slow and fail to detect many pathogens, including fastidious bacteria, anaerobes, and fungi. A new genomics-based urine assay using artificial intelligence (AI) now offers a faster, more accurate (97% sensitivity, 99% specificity), and comprehensive solution for identifying urogenital pathogens, including those often missed by traditional culture techniques.

The BIOTIA-ID urine NGS assay by Biotia (New York, NY, USA) combines AI and genomics, specifically shotgun metagenomic sequencing, to provide a comprehensive detection of pathogens, reducing false positives and overcoming the limitations of traditional methods such as culture, PCR, and targeted 16S amplicon next-generation sequencing (NGS), which frequently produce incomplete, unclear, or contradictory results. Powered by BIOTIA-DX software, this qualitative NGS-based in-vitro diagnostic test identifies clinically relevant urogenital pathogens from a database of over 7,000 clinically curated microbes. The test detects more than 30 pathogens known to cause UTIs, including fastidious bacteria, anaerobes, fungi, and polymicrobial infections.

BIOTIA-ID is designed specifically for high-risk patients with recurrent and complicated UTIs, serving as a reflex test for culture-negative specimens. This allows for a more targeted therapeutic approach based on the unique microbial profile of each patient’s sample. A recent clinical study showed the high performance of BIOTIA-ID, revealing that the assay identifies pathogens in 60% of urine samples where traditional culture methods fail. Alarmingly, 70% of these patients had previously been prescribed ineffective antimicrobials for the pathogens detected by BIOTIA-ID.

"Precision infectious disease diagnostics is not just about improving individual patient care; it is about transforming the healthcare landscape," said Dr. Niamh O'Hara, CEO and Co-Founder of Biotia. "By providing accurate, detailed, and timely information, we can move towards a future where treatment is truly personalized and public health is protected."

Related Links:
Biotia


Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
Gold Member
Auto Hematology Analyzer
DH-88CS [H]
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.